The role of RNA in mammalian prion protein conversion

Wiley Interdisciplinary Reviews: RNA

Volumn 3, Issue 3, 2012, Pages 415-428

  Gomes, Mariana P B ^a   Vieira, Tuane C R G ^a   Cordeiro, Yraima ^a   Silva, Jerson L ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSAMINOGLYCAN; NUCLEIC ACID; POLYANION; PRION PROTEIN; RNA; UNTRANSLATED RNA;

CATALYSIS; CELL DEATH; CELL FUNCTION; GENE CONVERSION; GENE FUNCTION; HUMAN; MAMMAL; NERVE CELL PLASTICITY; NONHUMAN; PRION DISEASE; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; RNA BINDING; TRANSCRIPTION REGULATION;

ANIMALS; CATALYSIS; GLYCOSAMINOGLYCANS; HUMANS; PRION DISEASES; PRIONS; RNA, UNTRANSLATED;

EID: 84867596659     PISSN: 17577004     EISSN: 17577012     Source Type: Journal    
DOI: 10.1002/wrna.118     Document Type: Review

References (152)

1. Aguzzi A, Polymenidou M. Mammalian prion biology: one century of evolving concepts. Cell 2004, 116:313-327.
2. Griffith JS. Self-replication and scrapie. Nature 1967, 215:1043-1044.
3. Prusiner SB. Prions. Proc Natl Acad Sci U S A 1998, 95:13363-13383.
4. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science 1982, 216:136-144.
5. Alper T, Haig DA, Clarke MC. The exceptionally small size of the scrapie agent. Biochem Biophys Res Commun 1966, 22:278-284.
6. Pattison IH. Resistance of the scrapie agent to formalin. J Comp Pathol 1965, 75:159-164.
7. Bueler H, Fischer M, Lang Y, Bluethmann H, Lipp HP, DeArmond SJ, Prusiner SB, Aguet M, Weissmann C. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature 1992, 356:577-582.
8. Bueler H, Aguzzi A, Sailer A, Greiner RA, Autenried P, Aguet M, Weissmann C. Mice devoid of PrP are resistant to scrapie. Cell 1993, 73:1339-1347.
9. Oesch B, Westaway D, Walchli M, McKinley MP, Kent SB, Aebersold R, Barry RA, Tempst P, Teplow DB, Hood LE. A cellular gene encodes scrapie PrP 27-30 protein. Cell 1985, 40:735-746.
10. Silva JL, Lima LM, Foguel D, Cordeiro Y. Intriguing nucleic-acid-binding features of mammalian prion protein. Trends Biochem Sci 2008, 33:132-140.
11. Lima LM, Cordeiro Y, Tinoco LW, Marques AF, Oliveira CL, Sampath S, Kodali R, Choi G, Foguel D, Torriani I, et al. Structural insights into the interaction between prion protein and nucleic acid. Biochemistry 2006, 45:9180-9187.
12. Cordeiro Y, Machado F, Juliano L, Juliano MA, Brentani RR, Foguel D, Silva JL. DNA converts cellular prion protein into the beta-sheet conformation and inhibits prion peptide aggregation. J Biol Chem 2001, 276:49400-49409.
13. Deleault NR, Harris BT, Rees JR, Supattapone S. Formation of native prions from minimal components in vitro. Proc Natl Acad Sci U S A 2007, 104:9741-9746.
14. Silva JL, Vieira TC, Gomes MP, Rangel LP, Scapin SM, Cordeiro Y. Experimental approaches to the interaction of the prion protein with nucleic acids and glycosaminoglycans: modulators of the pathogenic conversion. Methods 2011, 53:306-317.
15. Cashman NR, Loertscher R, Nalbantoglu J, Shaw I, Kascsak RJ, Bolton DC, Bendheim PE. Cellular isoform of the scrapie agent protein participates in lymphocyte activation. Cell 1990, 61:185-192.
16. Stahl N, Borchelt DR, Hsiao K, Prusiner SB. Scrapie prion protein contains a phosphatidylinositol glycolipid. Cell 1987, 51:229-240.
17. Rudd PM, Endo T, Colominas C, Groth D, Wheeler SF, Harvey DJ, Wormald MR, Serban H, Prusiner SB, Kobata A, et al. Glycosylation differences between the normal and pathogenic prion protein isoforms. Proc Natl Acad Sci U S A 1999, 96:13044-13049.
18. Rudd PM, Wormald MR, Wing DR, Prusiner SB, Dwek RA. Prion glycoprotein: structure, dynamics, and roles for the sugars. Biochemistry 2001, 40:3759-3766.
19. Viles JH, Cohen FE, Prusiner SB, Goodin DB, Wright PE, Dyson HJ. Copper binding to the prion protein: structural implications of four identical cooperative binding sites. Proc Natl Acad Sci U S A 1999, 96:2042-2047.
20. Brown DR, Qin K, Herms JW, Madlung A, Manson J, Strome R, Fraser PE, Kruck T, von Bohlen A, Schulz-Schaeffer W, et al. The cellular prion protein binds copper in vivo. Nature 1997, 390:684-687.
21. Riek R, Hornemann S, Wider G, Billeter M, Glockshuber R, Wuthrich K. NMR structure of the mouse prion protein domain PrP(121-321). Nature 1996, 382:180-182.
22. Riek R, Hornemann S, Wider G, Glockshuber R, Wuthrich K. NMR characterization of the full-length recombinant murine prion protein, mPrP(23-231). FEBS Lett 1997, 413:282-288.
23. Koradi R, Billeter M, Wuthrich K. MOLMOL: a program for display and analysis of macromolecular structures. J Mol Graph 1996, 14:29-32, 51-55.
24. Tjong H, Zhou HX. DISPLAR: an accurate method for predicting DNA-binding sites on protein surfaces. Nucleic Acids Res 2007, 35:1465-1477.
25. Pan KM, Baldwin M, Nguyen J, Gasset M, Serban A, Groth D, Mehlhorn I, Huang Z, Fletterick RJ, Cohen FE. Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci U S A 1993, 90:10962-10966.
26. Tycko R, Savtchenko R, Ostapchenko VG, Makarava N, Baskakov IV. The alpha-helical C-terminal domain of full-length recombinant PrP converts to an in-register parallel beta-sheet structure in PrP fibrils: evidence from solid state nuclear magnetic resonance. Biochemistry 2010, 49:9488-9497.
27. Huang Z, Prusiner SB, Cohen FE. Scrapie prions: a three-dimensional model of an infectious fragment. Fold Des 1996, 1:13-19.
28. Caughey B, Raymond GJ. The scrapie-associated form of PrP is made from a cell surface precursor that is both protease- and phospholipase-sensitive. J Biol Chem 1991, 266:18217-18223.
29. Govaerts C, Wille H, Prusiner SB, Cohen FE. Evidence for assembly of prions with left-handed beta-helices into trimers. Proc Natl Acad Sci U S A 2004, 101:8342-8347.
30. Baskakov IV, Legname G, Prusiner SB, Cohen FE. Folding of prion protein to its native alpha-helical conformation is under kinetic control. J Biol Chem 2001, 276:19687-19690.
31. Cohen FE, Prusiner SB. Pathologic conformations of prion proteins. Annu Rev Biochem 1998, 67:793-819.
32. Kocisko DA, Priola SA, Raymond GJ, Chesebro B, Lansbury PT Jr, Caughey B. Species specificity in the cell-free conversion of prion protein to protease-resistant forms: a model for the scrapie species barrier. Proc Natl Acad Sci U S A 1995, 92:3923-3927.
33. Kocisko DA, Come JH, Priola SA, Chesebro B, Raymond GJ, Lansbury PT, Caughey B. Cell-free formation of protease-resistant prion protein. Nature 1994, 370:471-474.
34. Weissmann C. The state of the prion. Nat Rev Microbiol 2004, 2:861-871.
35. Deleault NR, Lucassen RW, Supattapone S. RNA molecules stimulate prion protein conversion. Nature 2003, 425:717-720.
36. Caughey B, Race RE. Scrapie-associated PrP accumulation and its inhibition: revisiting the amyloid-glycosaminoglycan connection. Ann N Y Acad Sci 1994, 724:290-295.
37. Riesner D. Biochemistry and structure of PrP(C) and PrP(Sc). Br Med Bull 2003, 66:21-33.
38. Hafner-Bratkovic I, Bester R, Pristovsek P, Gaedtke L, Veranic P, Gaspersic J, Mancek-Keber M, Avbelj M, Polymenidou M, Julius C, et al. Globular domain of the prion protein needs to be unlocked by domain swapping to support prion protein conversion. J Biol Chem 2011, 286:12149-12156.
39. Linden R, Martins VR, Prado MA, Cammarota M, Izquierdo I, Brentani RR. Physiology of the prion protein. Physiol Rev 2008, 88:673-728.
40. Martins VR, Linden R, Prado MA, Walz R, Sakamoto AC, Izquierdo I, Brentani RR. Cellular prion protein: on the road for functions. FEBS Lett 2002, 512:25-28.
41. Graner E, Mercadante AF, Zanata SM, Forlenza OV, Cabral AL, Veiga SS, Juliano MA, Roesler R, Walz R, Minetti A, et al. Cellular prion protein binds laminin and mediates neuritogenesis. Brain Res Mol Brain Res 2000, 76:85-92.
42. Graner E, Mercadante AF, Zanata SM, Martins VR, Jay DG, Brentani RR. Laminin-induced PC-12 cell differentiation is inhibited following laser inactivation of cellular prion protein. FEBS Lett 2000, 482:257-260.
43. Zanata SM, Lopes MH, Mercadante AF, Hajj GN, Chiarini LB, Nomizo R, Freitas AR, Cabral AL, Lee KS, Juliano MA, et al. Stress-inducible protein 1 is a cell surface ligand for cellular prion that triggers neuroprotection. EMBO J 2002, 21:3307-3316.
44. Romano SA, Cordeiro Y, Lima LM, Lopes MH, Silva JL, Foguel D, Linden R. Reciprocal remodeling upon binding of the prion protein to its signaling partner hop/STI1. FASEB J 2009, 23:4308-4316.
45. Prusiner SB, Groth D, Serban A, Stahl N, Gabizon R. Attempts to restore scrapie prion infectivity after exposure to protein denaturants. Proc Natl Acad Sci U S A 1993, 90:2793-2797.
46. Hill AF, Antoniou M, Collinge J. Protease-resistant prion protein produced in vitro lacks detectable infectivity. J Gen Virol 1999, 80(pt 1):11-14.
47. Shaked GM, Fridlander G, Meiner Z, Taraboulos A, Gabizon R. Protease-resistant and detergent-insoluble prion protein is not necessarily associated with prion infectivity. J Biol Chem 1999, 274:17981-17986.
48. Nandi PK, Leclerc E. Polymerization of murine recombinant prion protein in nucleic acid solution. Arch Virol 1999, 144:1751-1763.
49. Saborio GP, Permanne B, Soto C. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature 2001, 411:810-813.
50. Lucassen R, Nishina K, Supattapone S. In vitro amplification of protease-resistant prion protein requires free sulfhydryl groups. Biochemistry 2003, 42: 4127-4135.
51. Wang F, Wang X, Yuan CG, Ma J. Generating a prion with bacterially expressed recombinant prion protein. Science 2010, 327:1132-1135.
52. Caughey B, Kocisko DA. Prion diseases - a nucleic-acid accomplice? Nature 2003, 425:673-674.
53. Baskakov IV, Legname G, Baldwin MA, Prusiner SB, Cohen FE. Pathway complexity of prion protein assembly into amyloid. J Biol Chem 2002, 277:21140-21148.
54. Cordeiro Y, Silva JL. The hypothesis of the catalytic action of nucleic acid on the conversion of prion protein. Protein Pept Lett 2005, 12:251-255.
55. Caughey B, Brown K, Raymond GJ, Katzenstein GE, Thresher W. Binding of the protease-sensitive form of PrP (prion protein) to sulfated glycosaminoglycan and congo red [corrected]. J Virol 1994, 68:2135-2141.
56. Horonchik L, Tzaban S, Ben Zaken O, Yedidia Y, Rouvinski A, Papy-Garcia D, Barritault D, Vlodavsky I, Taraboulos A. Heparan sulfate is a cellular receptor for purified infectious prions. J Biol Chem 2005, 280:17062-17067.
57. Prusiner SB, DeArmond SJ. Prion diseases and neurodegeneration. Annu Rev Neurosci 1994, 17: 311-339.
58. Kampa D, Cheng J, Kapranov P, Yamanaka M, Brubaker S, Cawley S, Drenkow J, Piccolboni A, Bekiranov S, Helt G, et al. Novel RNAs identified from an in-depth analysis of the transcriptome of human chromosomes 21 and 22. Genome Res 2004, 14:331-342.
59. Costa F. Non-coding RNAs: new players in eukaryotic biology. Gene 2005, 357:83-94.
60. Dinger ME, Mercer TR, Mattick JS. RNAs as extracellular signaling molecules. J Mol Endocrinol 2008, 40:151-159.
61. Jha S, Komar AA. Birth, life and death of nascent polypeptide chains. Biotechnol J 2011, 6:623-640.
62. Voisset C, Saupe SJ, Blondel M. The various facets of the protein-folding activity of the ribosome. Biotechnol J 2011, 6:668-673.
63. Tribouillard-Tanvier D, Dos Reis S, Gug F, Voisset C, Beringue V, Sabate R, Kikovska E, Talarek N, Bach S, Huang C, et al. Protein folding activity of ribosomal RNA is a selective target of two unrelated antiprion drugs. PLoS One 2008, 3:e2174.
64. Taft RJ, Pheasant M, Mattick JS. The relationship between non-protein-coding DNA and eukaryotic complexity. Bioessays 2007, 29:288-299.
65. Taft RJ, Pang KC, Mercer TR, Dinger M, Mattick JS. Non-coding RNAs: regulators of disease. J Pathol 2010, 220:126-139.
66. Montgomery MK, Xu S, Fire A. RNA as a target of double-stranded RNA-mediated genetic interference in Caenorhabditis elegans. Proc Natl Acad Sci U S A 1998, 95:15502-15507.
67. Timmons L, Fire A. Specific interference by ingested dsRNA. Nature 1998, 395:854.
68. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811.
69. Costa FF. Non-coding RNAs: lost in translation? Gene 2007, 386:1-10.
70. Musunuru K. Cell-specific RNA-binding proteins in human disease. Trends Cardiovasc Med 2003, 13:188-195.
71. Hogan DJ, Riordan DP, Gerber AP, Herschlag D, Brown PO. Diverse RNA-binding proteins interact with functionally related sets of RNAs, suggesting an extensive regulatory system. PLoS Biol 2008, 6:e255.
72. Lukiw WJ, Handley P, Wong L, Crapper McLachlan DR. BC200 RNA in normal human neocortex, non-Alzheimer dementia (NAD), and senile dementia of the Alzheimer type (AD). Neurochem Res 1992, 17:591-597.
73. Smith P, Al Hashimi A, Girard J, Delay C, Hébert SS. In vivo regulation of amyloid precursor protein neuronal splicing by microRNAs. J Neurochem 2011, 116:240-247.
74. Adler V, Zeiler B, Kryukov V, Kascsak R, Rubenstein R, Grossman A. Small, highly structured RNAs participate in the conversion of human recombinant PrP(Sen) to PrP(Res) in vitro. J Mol Biol 2003, 332:47-57.
75. Nandi PK, Nicole JC. Nucleic acid and prion protein interaction produces spherical amyloids which can function in vivo as coats of spongiform encephalopathy agent. J Mol Biol 2004, 344:827-837.
76. Supattapone S. Prion protein conversion in vitro. J Mol Med 2004, 82:348-356.
77. Scott WG. Ribozymes. Curr Opin Struct Biol 2007, 17:280-286.
78. Gomes MP, Cordeiro Y, Silva JL. The peculiar interaction between mammalian prion protein and RNA. Prion 2008, 2:64-66.
79. McKinley MP, Bolton DC, Prusiner SB. A protease-resistant protein is a structural component of the scrapie prion. Cell 1983, 35:57-62.
80. Bolton DC, McKinley MP, Prusiner SB. Molecular characteristics of the major scrapie prion protein. Biochemistry 1984, 23:5898-5906.
81. Prusiner SB, Groth DF, Bolton DC, Kent SB, Hood LE. Purification and structural studies of a major scrapie prion protein. Cell 1984, 38:127-134.
82. Gomes MP, Millen TA, Ferreira PS, Cunha e Silva NL, Vieira TC, Almeida MS, Silva JL, Cordeiro Y. Prion protein complexed to N2a cellular RNAs through its N-terminal domain forms aggregates and is toxic to murine neuroblastoma cells. J Biol Chem 2008, 283:19616-19625.
83. Geoghegan JC, Valdes PA, Orem NR, Deleault NR, Williamson RA, Harris BT, Supattapone S. Selective incorporation of polyanionic molecules into hamster prions. J Biol Chem 2007, 282:36341-36353.
84. Weiss S, Proske D, Neumann M, Groschup MH, Kretzschmar HA, Famulok M, Winnacker EL. RNA aptamers specifically interact with the prion protein PrP. J Virol 1997, 71:8790-8797.
85. Nandi PK. Interaction of prion peptide HuPrP106-126 with nucleic acid. Arch Virol 1997, 142:2537-2545.
86. Rhie A, Kirby L, Sayer N, Wellesley R, Disterer P, Sylvester I, Gill A, Hope J, James W, Tahiri-Alaoui A. Characterization of 2'-fluoro-RNA aptamers that bind preferentially to disease-associated conformations of prion protein and inhibit conversion. J Biol Chem 2003, 278:39697-39705.
87. Sayer NM, Cubin M, Rhie A, Bullock M, Tahiri-Alaoui A, James W. Structural determinants of conformationally selective, prion-binding aptamers. J Biol Chem 2004, 279:13102-13109.
88. Kocisko DA, Vaillant A, Lee KS, Arnold KM, Bertholet N, Race RE, Olsen EA, Juteau JM, Caughey B. Potent antiscrapie activities of degenerate phosphorothioate oligonucleotides. Antimicrob Agents Chemother 2006, 50:1034-1044.
89. Takemura K, Wang P, Vorberg I, Surewicz W, Priola SA, Kanthasamy A, Pottathil R, Chen SG, Sreevatsan S. DNA aptamers that bind to PrP(C) and not PrP(Sc) show sequence and structure specificity. Exp Biol Med (Maywood) 2006, 231:204-214.
90. Deleault NR, Kascsak R, Geoghegan JC, Supattapone S. Species-dependent differences in cofactor utilization for formation of the protease-resistant prion protein in vitro. Biochemistry 2010, 49:3928-3934.
91. Deleault NR, Geoghegan JC, Nishina K, Kascsak R, Williamson RA, Supattapone S. Protease-resistant prion protein amplification reconstituted with partially purified substrates and synthetic polyanions. J Biol Chem 2005, 280:26873-26879.
92. Nandi PK, Leclerc E, Nicole JC, Takahashi M. DNA-induced partial unfolding of prion protein leads to its polymerisation to amyloid. J Mol Biol 2002, 322:153-161.
93. Supattapone S, Deleault NR, Rees JR. Amplification of purified prions in vitro. Methods Mol Biol 2008, 459:117-130.
94. Piro JR, Harris BT, Supattapone S. In situ photodegradation of incorporated polyanion does not alter prion infectivity. PLoS Pathog 2011, 7:e1002001.
95. Ben Zaken O, Tzaban S, Tal Y, Horonchik L, Esko JD, Vlodavsky I, Taraboulos A. Cellular heparan sulfate participates in the metabolism of prions. J Biol Chem 2003, 278:40041-40049.
96. Iozzo RV. Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem 1998, 67:609-652.
97. Sasisekharan R, Raman R, Prabhakar V. Glycomics approach to structure-function relationships of glycosaminoglycans. Annu Rev Biomed Eng 2006, 8:181-231.
98. Snow AD, Wight TN, Nochlin D, Koike Y, Kimata K, DeArmond SJ, Prusiner SB. Immunolocalization of heparan sulfate proteoglycans to the prion protein amyloid plaques of Gerstmann-Straussler syndrome, Creutzfeldt-Jakob disease and scrapie. Lab Invest 1990, 63:601-611.
99. Wong C, Xiong LW, Horiuchi M, Raymond L, Wehrly K, Chesebro B, Caughey B. Sulfated glycans and elevated temperature stimulate PrP(Sc)-dependent cell-free formation of protease-resistant prion protein. EMBO J 2001, 20:377-386.
100. Priola SA, Caughey B. Inhibition of scrapie-associated PrP accumulation. Probing the role of glycosaminoglycans in amyloidogenesis. Mol Neurobiol 1994, 8:113-120.
101. Vieira TC, Reynaldo DP, Gomes MP, Almeida MS, Cordeiro Y, Silva JL. Heparin binding by murine recombinant prion protein leads to transient aggregation and formation of RNA-resistant species. J Am Chem Soc 2011, 133:334-344.
102. Shyng SL, Moulder KL, Lesko A, Harris DA. The N-terminal domain of a glycolipid-anchored prion protein is essential for its endocytosis via clathrin-coated pits. J Biol Chem 1995, 270:14793-14800.
103. Godsave SF, Wille H, Kujala P, Latawiec D, DeArmond SJ, Serban A, Prusiner SB, Peters PJ. Cryo-immunogold electron microscopy for prions: toward identification of a conversion site. J Neurosci 2008, 28:12489-12499.
104. McKinley MP, Taraboulos A, Kenaga L, Serban D, Stieber A, DeArmond SJ, Prusiner SB, Gonatas N. Ultrastructural localization of scrapie prion proteins in cytoplasmic vesicles of infected cultured cells. Lab Invest 1991, 65:622-630.
105. Arnold JE, Tipler C, Laszlo L, Hope J, Landon M, Mayer RJ. The abnormal isoform of the prion protein accumulates in late-endosome-like organelles in scrapie-infected mouse brain. J Pathol 1995, 176:403-411.
106. Marijanovic Z, Caputo A, Campana V, Zurzolo C. Identification of an intracellular site of prion conversion. PLoS Pathog 2009, 5:e1000426.
107. Shyng SL, Huber MT, Harris DA. A prion protein cycles between the cell surface and an endocytic compartment in cultured neuroblastoma cells. J Biol Chem 1993, 268:15922-15928.
108. Sunyach C, Jen A, Deng J, Fitzgerald KT, Frobert Y, Grassi J, McCaffrey MW, Morris R. The mechanism of internalization of glycosylphosphatidylinositol-anchored prion protein. EMBO J 2003, 22: 3591-3601.
109. Borchelt DR, Taraboulos A, Prusiner SB. Evidence for synthesis of scrapie prion proteins in the endocytic pathway. J Biol Chem 1992, 267:16188-16199.
110. Campana V, Sarnataro D, Zurzolo C. The highways and byways of prion protein trafficking. Trends Cell Biol 2005, 15:102-111.
111. Cheng F, Lindqvist J, Haigh CL, Brown DR, Mani K. Copper-dependent co-internalization of the prion protein and glypican-1. J Neurochem 2006, 98:1445-1457.
112. Ladogana A, Casaccia P, Ingrosso L, Cibati M, Salvatore M, Xi YG, Masullo C, Pocchiari M. Sulphate polyanions prolong the incubation period of scrapie-infected hamsters. J Gen Virol 1992, 73(pt 3):661-665.
113. Ouidja MO, Petit E, Kerros ME, Ikeda Y, Morin C, Carpentier G, Barritault D, Brugere-Picoux J, Deslys JP, Adjou K, et al. Structure-activity studies of heparan mimetic polyanions for anti-prion therapies. Biochem Biophys Res Commun 2007, 363:95-100.
114. Sharp KA, Honig B. Electrostatic interactions in macromolecules: theory and applications. Annu Rev Biophys Biophys Chem 1990, 19:301-332.
115. Perutz MF. Electrostatic effects in proteins. Science 1978, 201:1187-1191.
116. Oberoi H, Trikha J, Yuan X, Allewell NM. Identification and analysis of long-range electrostatic effects in proteins by computer modeling:aspartate transcarbamylase. Proteins 1996, 25:300-314.
117. Hendsch ZS, Tidor B. Do salt bridges stabilize proteins? A continuum electrostatic analysis. Protein Sci 1994, 3:211-226.
118. Pixley RA, Lin Y, Isordia-Salas I, Colman RW. Fine mapping of the sequences in domain 5 of high molecular weight kininogen (HK) interacting with heparin and zinc. J Thromb Haemost 2003, 1:1791-1798.
119. Abedini A, Tracz SM, Cho JH, Raleigh DP. Characterization of the heparin binding site in the N-terminus of human pro-islet amyloid polypeptide: implications for amyloid formation. Biochemistry 2006, 45:9228-9237.
120. Chen YC, Lim C. Common physical basis of macromolecule-binding sites in proteins. Nucleic Acids Res 2008, 36:7078-7087.
121. Warner RG, Hundt C, Weiss S, Turnbull JE. Identification of the heparan sulfate binding sites in the cellular prion protein. J Biol Chem 2002, 277:18421-18430.
122. Vieira TCRG. Aspectos estruturais da interação entre a proteína do prion e heparina. Rio de Janeiro: Universidade Federal do Rio de Janeiro; 2009.
123. Gomes MPB. Interação PrP-RNA: aspectos estruturais e estudos de toxicicidade. Rio de Janeiro: Universidade Federal do Rio de Janeiro; 2011.
124. Seyrek E, Dubin PL, Tribet C, Gamble EA. Ionic strength dependence of protein-polyelectrolyte interactions. Biomacromolecules 2003, 4:273-282.
125. Seyrek E, Dubin P. Glycosaminoglycans as polyelectrolytes. Adv Colloid Interface Sci 2010, 158:119-129.
126. King DJ, Safar JG, Legname G, Prusiner SB. Thioaptamer interactions with prion proteins: sequence-specific and non-specific binding sites. J Mol Biol 2007, 369:1001-1014.
127. Sekiya S, Noda K, Nishikawa F, Yokoyama T, Kumar PK, Nishikawa S. Characterization and application of a novel RNA aptamer against the mouse prion protein. J Biochem 2006, 139:383-390.
128. Ivanyi-Nagy R, Davidovic L, Khandjian EW, Darlix JL. Disordered RNA chaperone proteins: from functions to disease. Cell Mol Life Sci 2005, 62:1409-1417.
129. Gabus C, Derrington E, Leblanc P, Chnaiderman J, Dormont D, Swietnicki W, Morillas M, Surewicz WK, Marc D, Nandi P, et al. The prion protein has RNA binding and chaperoning properties characteristic of nucleocapsid protein NCP7 of HIV-1. J Biol Chem 2001, 276:19301-19309.
130. Ameres SL, Martinez J, Schroeder R. Molecular basis for target RNA recognition and cleavage by human RISC. Cell 2007, 130:101-112.
131. Cristofari G, Darlix JL. The ubiquitous nature of RNA chaperone proteins. Prog Nucleic Acid Res Mol Biol 2002, 72:223-268.
132. Clodi E, Semrad K, Schroeder R. Assaying RNA chaperone activity in vivo using a novel RNA folding trap. EMBO J 1999, 18:3776-3782.
133. Derrington E, Gabus C, Leblanc P, Chnaidermann J, Grave L, Dormont D, Swietnicki W, Morillas M, Marck D, Nandi P, et al. PrPC has nucleic acid chaperoning properties similar to the nucleocapsid protein of HIV-1. C R Biol 2002, 325:17-23.
134. Moscardini M, Pistello M, Bendinelli M, Ficheux D, Miller JT, Gabus C, Le Grice SF, Surewicz WK, Darlix JL. Functional interactions of nucleocapsid protein of feline immunodeficiency virus and cellular prion protein with the viral RNA. J Mol Biol 2002, 318:149-159.
135. Bera A, Roche AC, Nandi PK. Bending and unwinding of nucleic acid by prion protein. Biochemistry 2007, 46:1320-1328.
136. Millen TA. Características estruturais e toxicológicas de isoformas da proteína do prion. Rio de Janeiro: Universidade Federal do Rio de Janeiro; 2007.
137. Beaudoin S, Vanderperre B, Grenier C, Tremblay I, Leduc F, Roucou X. A large ribonucleoprotein particle induced by cytoplasmic PrP shares striking similarities with the chromatoid body, an RNA granule predicted to function in posttranscriptional gene regulation. Biochim Biophys Acta 2009, 1793:335-345.
138. Tompa P, Csermely P. The role of structural disorder in the function of RNA and protein chaperones. FASEB J 2004, 18:1169-1175.
139. Si K, Lindquist S, Kandel ER. A neuronal isoform of the aplysia CPEB has prion-like properties. Cell 2003, 115:879-891.
140. Si K, Choi YB, White-Grindley E, Majumdar A, Kandel ER. Aplysia CPEB can form prion-like multimers in sensory neurons that contribute to long-term facilitation. Cell 2011, 140:421-435.
141. Wickner RB, Edskes HK, Shewmaker FP, Kryndushkin D, Nemecek J, McGlinchey R, Bateman D. The relationship of prions and translation. WIREs RNA 2011, 1:81-89.
142. Tribouillard-Tanvier D, Beringue V, Desban N, Gug F, Bach S, Voisset C, Galons H, Laude H, Vilette D, Blondel M. Antihypertensive drug guanabenz is active in vivo against both yeast and mammalian prions. PLoS One 2008, 3:e1981.
143. Bach S, Talarek N, Andrieu T, Vierfond JM, Mettey Y, Galons H, Dormont D, Meijer L, Cullin C, Blondel M. Isolation of drugs active against mammalian prions using a yeast-based screening assay. Nat Biotechnol 2003, 21:1075-1081.
144. Bach S, Tribouillard D, Talarek N, Desban N, Gug F, Galons H, Blondel M. A yeast-based assay to isolate drugs active against mammalian prions. Methods 2006, 39:72-77.
145. Adjou KT, Simoneau S, Sales N, Lamoury F, Dormont D, Papy-Garcia D, Barritault D, Deslys JP, Lasmezas CI. A novel generation of heparan sulfate mimetics for the treatment of prion diseases. J Gen Virol 2003, 84:2595-2603.
146. Edgeworth JA, Gros N, Alden J, Joiner S, Wadsworth JD, Linehan J, Brandner S, Jackson GS, Weissmann C, Collinge J. Spontaneous generation of mammalian prions. Proc Natl Acad Sci U S A 2010, 107:14402-14406.
147. Frost B, Diamond MI. Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci 2010, 11:155-159.
148. Ishimaru D, Ano Bom AP, Lima LM, Quesado PA, Oyama MF, de Moura Gallo CV, Cordeiro Y, Silva JL. Cognate DNA stabilizes the tumor suppressor p53 and prevents misfolding and aggregation. Biochemistry 2009, 48:6126-6135.
149. Ishimaru D, Andrade LR, Teixeira LS, Quesado PA, Maiolino LM, Lopez PM, Cordeiro Y, Costa LT, Heckl WM, Weissmuller G, et al. Fibrillar aggregates of the tumor suppressor p53 core domain. Biochemistry 2003, 42:9022-9027.
150. Silva JL, Vieira TC, Gomes MP, Bom AP, Lima LM, Freitas MS, Ishimaru D, Cordeiro Y, Foguel D. Ligand binding and hydration in protein misfolding: insights from studies of prion and p53 tumor suppressor proteins. Acc Chem Res 2010, 43:271-279.
151. Jimenez JS. Protein-DNA interaction at the origin of neurological diseases: a hypothesis. J Alzheimers Dis 2010, 22:375-391.
152. Giraldo R. Defined DNA sequences promote the assembly of a bacterial protein into distinct amyloid nanostructures. Proc Natl Acad Sci U S A 2007, 104:17388-17393.